Ezetimibe/Rosuvastatin Calcium

依折麦布/瑞舒伐他汀钙

Report date: 2025/03/10 14:56:25

Base Information

Drug NameEzetimibe/Rosuvastatin Calcium
Drug Alias Name瑞舒伐他汀钙/依折麦布Rosuvastatin Calcium/Ezetimibeezetimibe + rosuvastatin calcium瑞舒伐他汀依折麦布Rosuvamibe +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHMG-CoA reductase inhibitorsCholesterol absorption inhibitorsNiemann-Pick C1-like protein 1 inhibitors
TargetsHMG-CoA reductaseNiemann-Pick C1-like protein 1
Therapy Area/IndicationsHomozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[4] 
Global Approved IndicationsHomozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias
Approved Indications in ChinaHomozygous familial hypercholesterolemiaHypercholesterolemia
Original Approved Country/TerritoryAustralia
Original Approved Date2014/01/01
Country/TerritoryUnited StatesAustraliaSouth Korea +[4] 
CombinationsYes EzetimibeRosuvastatin Calcium
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLCSanofi ChinaAlthera Laboratories Ltd
Inactive CompaniesHanmi Pharmaceutical Co LtdNvp HealthcareSanofi-Aventis Ireland Ltd +[7] 
Active IndicationsHomozygous familial hypercholesterolemiaHypercholesterolemia
Inactive IndicationsHyperlipidemiasDyslipidemias

Other Information

ATC CodeC10BA
Related LinksN/A